Do CTLA4 rs231775, CD40 rs1883832, and HLA-DQA1 rs2187668 indicate higher autoimmune susceptibility?

Autoimmune thyroid diseases (AITD), such as Graves' disease and Hashimoto's thyroiditis, are heavily influenced by key genetic variations that disrupt immune tolerance and drive systemic autoimmunity.

Genetic susceptibility and mechanistic pathways

• CTLA4 rs231775 (+49A/G): The G allele causes an amino acid substitution that reduces CTLA-4 cell surface expression on T-cells, diminishing inhibitory signaling and leading to elevated, unchecked T-cell activation.
• CD40 rs1883832 (-1C>T): Located in the Kozak sequence, the C risk allele increases CD40 translational efficiency. This upregulates CD40 expression on B-cells and thyroid tissue, enhancing T-B cell interactions and B-cell activation.
• HLA-DQA1 rs2187668: This serves as a key tag SNP for the high-risk HLA-DR3-DQ2.5 haplotype (DRB103:01-DQA105:01-DQB1*02:01), conferring broad susceptibility to multi-organ autoimmune clustering.

Thyroid-directed antibody activity

• CD40 and TRAb: The CD40 rs1883832 C allele is strongly linked to Graves' disease risk and elevated TSH-receptor autoantibodies (TRAb), though it is not a primary driver of isolated anti-TPO or anti-Tg activity.
• CTLA4 and AITD: The CTLA4 rs231775 G allele correlates with overall AITD risk, impacting both TRAb in Graves' disease and anti-TPO/anti-Tg antibodies in Hashimoto's thyroiditis.
• HLA-DQA1 and clustering: Although HLA-DQA1 rs2187668 acts primarily as a generalized autoimmune risk marker, the DR3-DQ2.5 background it tags promotes the systemic immune dysregulation that underlies thyroid-directed autoantibody activity.

Bottom line

• The CTLA4 rs231775, CD40 rs1883832, and HLA-DQA1 rs2187668 variants represent established genetic risk markers that drive systemic immune dysregulation, directly modulating thyroid-directed autoantibody production in Graves' disease and Hashimoto's thyroiditis.